MARKET

AGIO

AGIO

Agios Pharmaceuticals Inc
NASDAQ
30.93
+0.61
+2.01%
After Hours: 30.93 0 0.00% 16:01 02/07 EST
OPEN
30.29
PREV CLOSE
30.32
HIGH
31.13
LOW
29.88
VOLUME
738.32K
TURNOVER
0
52 WEEK HIGH
34.76
52 WEEK LOW
16.75
MARKET CAP
1.70B
P/E (TTM)
-4.6032
1D
5D
1M
3M
1Y
5Y
Piper Sandler Initiates Coverage On Agios Pharmaceuticals with Overweight Rating, Announces Price Target of $41
Benzinga · 4d ago
--Piper Sandler Starts Agios Pharmaceuticals at Overweight With $41 Price Target
--Piper Sandler Starts Agios Pharmaceuticals at Overweight With $41 Price Target
MT Newswires · 4d ago
Insider Sell: Agios Pharmaceuticals
Insider Sell: Agios Pharmaceuticals
MT Newswires · 6d ago
BRIEF-Agios Presents Updated Pyrukynd Long-Term Extension Data
Reuters · 12/12/2022 00:11
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition
– Data Suggest Long-term Treatment with PYRUKYND® in Adults with PK Deficiency is Associated with Improvements in Hemoglobin, Iron Overload, Transfusion Burden and Patient-reported Outcomes, Regardless of Transfusion Status – – Additional Data Presented at...
GlobeNewswire · 12/12/2022 00:00
BRIEF-Agios Presents Updated Pyrukynd Data Highlighting Long-Term Safety Profile
Reuters · 12/11/2022 00:03
Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meeting and Exposition
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependent α- or β-Thalassemia, Respectively – – Agios to Host Live and Webcast Investor Event on Dec. 12, 2022, at 7 ...
GlobeNewswire · 12/10/2022 23:30
Agios Appoints Tsveta Milanova as Chief Commercial Officer
CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the appointment of Tsveta Milanova to the role of chief com...
GlobeNewswire · 12/06/2022 12:00
More
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (L-IR MDS), which is in Phase I clinical study.

Webull offers kinds of Agios Pharmaceuticals Inc stock information, including NASDAQ:AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGIO stock methods without spending real money on the virtual paper trading platform.